No Data
ACELYRIN, INC. to Host Virtual Investor Event to Share New Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
Why Is Acelyrin, Inc. (SLRN) Among the Best Biotech Penny Stocks to Invest in Now?
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $5
Hold Rating Maintained for ACELYRIN, INC. Amidst Izokibep Study Setback and Revised Sales Projections
Acelyrin Price Target Lowered to $5 From $6 at Morgan Stanley